05:47 AM EDT, 09/22/2025 (MT Newswires) -- Pfizer ( PFE ) is on the verge of finalizing a potential $7.3 billion deal to acquire anti-obesity drug developer Metsera ( MTSR ) , The Wall Street Journal reported Monday, citing people familiar with the matter.

Under the proposed deal, Pfizer ( PFE ) would pay Metsera ( MTSR ) $47.50 in cash per share and another $22.50 if certain performance milestones are met, valuing the company at up to $7.3 billion, the report said.

The deal could be announced as early as Monday, the report said.

Pfizer ( PFE ) and Metsera ( MTSR ) did not immediately reply to requests for comment.

Shares of Metsera ( MTSR ) were up 50% in recent premarket activity Monday, while Pfizer ( PFE ) shares were up 2%.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)